Meeting Room: Room 331, Level 3, Suntec Singapore
|
Time
|
Programme
|
09:00 – 09:30
|
Special Lecture
|
Chair and Moderator: Gary Levy (Canada)
|
09:00 – 09:15
|
Entry Inhibitor Alone or with Antiviral Therapy to Treat HBV
|
Stephan Urban, Germany
|
09:15 – 09:30
|
Discussion Forum led by the Moderator
|
09:30 – 10:15
|
Debate: Can HBV be Cured by Antiviral Therapy Alone?
|
Chair and Moderator: Stephen Locarnini (Australia)
|
09:30 – 10:00
|
· Yes: Fabien Zoulim, France
|
· No: Antonio Bertoletti, Singapore
|
10:00 – 10:15
|
Discussion Forum led by the Moderator
|
10:15 – 11:30
|
Immunology Forum Part 1
|
Chair and Moderator: Jonathan Karn (USA)
|
10:15 – 10:30
|
Immune Correlates of HBsAg Clearance
|
Robert Thimme, Germany
|
10:30 – 10:45
|
The Role of Innnate Immunity in Functional Cure
|
Fabien Zoulim, France
|
Invited Oral & Free Paper Presentations
|
10:45 – 10:55
|
Modulating the Immune Response for HBV Cure
|
Audrey Lau, Gilead Sciences
|
10:55 – 11:05
|
Update on Inarigivir, a Novel RIG-I agonist to Stimulate Innate Immunity and Promote Functional Cure in Chronic HBV
|
Nezam H. Afdhal, Spring Bank Pharmaceuticals
|
11:05 – 11:15
|
A Randomized, Placebo-controlled, Blinded Phase 1B Study Evaluating the Oral TLR8 Agonist GS-9688 In Patients with Chronic Hepatitis B (CHB)
|
Edward Gane, New Zealand
|
11:15 – 11:30
|
Discussion Forum led by the Moderator
|
11:30 – 11:45
|
Tea Break
|
11:45 – 13:00
|
Immunology Forum Part 2
|
Chair and Moderator: Fabien Zoulim (France)
|
11:45 – 12:00
|
Overview of Adaptive Immune Therapies for CHB
|
Robert Thimme, Germany
|
12:00 – 12:15
|
Car-T therapy: Principles and Applicability
|
Jonathan Karn, USA
|
Invited Oral & Free Paper Presentations
|
12:15 – 12:25
|
HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy
|
Christine, Y.L. Tham, Singapore
|
12:25 – 12:35
|
Viral-hijacked monocytic myeloid-derived suppressor cells promote clonal deletion of hepatitis B surface antigen-specific CD8+ thymocytes
|
Zhong Fang, China
|
12:35 – 12:45
|
Comparative Characterization of B cells Specific for HBV Nucleocapside and Envelope Proteins in Patients with Chronic Hepatitis B
|
Loghman Salimzadeh, Singapore
|
12:45 – 13:00
|
Discussion Forum led by the Moderator
|
13:00 – 14:00
|
Lunch
|
14:00 – 15:10
|
Reducing Viral Antigens
|
Chair and Moderator: Massimo Levrero (France)
|
14:00 – 14:15
|
Differential Cytokine and Chemokine Response Resulting in loss of HBsAg in CHB Patients undergoing IFN-alpha Therapy
|
John Connolly, Singapore
|
14:15– 14:30:
|
The Role of Plasmacytoid Dendritic Cells During HBeAg Seroconversion
|
Sriram Narayanan, Singapore
|
Invited Oral & Free Paper Presentations
|
14:30 – 14:40
|
RNAi: Pulling Us Toward Finite Therapy
|
Bruce Given, Arrowhead Pharmaceuticals
|
14:40 – 14:50
|
Targeting HBV Using Immune Mobilising Monoclonal TCRS Against Virus (Immtav®)
|
Praveen Kumar Singh, Immunocore
|
14:50 – 15:10
|
Discussion Forum led by the Moderator
|
15:10 – 16:10
|
Combination Therapy Symposium
|
Chair and Moderator: Seng Gee Lim (Singapore)
|
15:10 – 15:25
|
Studies of Combination Antiviral Therapy – what works and what doesn’t
|
Jorg Peterson, Germany
|
15:25 – 15:40
| Small Dataset AI Analytics for Rational Drug Combination Design
|
Edward Chow Singapore
|
15:40 – 15:55
|
Establishing functional cure of chronic HBV infection with nucleic acid polymers: Final results of the REP 401 study
|
Andrew Vaillant, Replicor Inc
|
|
15:55 – 16:10
|
Tea Break
|
16:10 – 17:30 |
Combination Therapy Forum
|
Moderator: Edward Gane (New Zealand)
|
16:10 – 17:30
|
Robert Gish (USA), Stephan Urban (Germany), Robert Thimme (Germany), Nezam H. Afdhal (Spring Bank Pharmaceuticals), Andrew Vaillant (Replicor Inc), Cynthia Wat (Roche), Oliver Lenz (Janssen Pharmaceutica), Bruce Given (Arrowhead Pharmaceuticals), Audrey Lau (Gilead Sciences), Jean-François Rossignol (Romark, L.C), Gavin Cloherty (Abbott Diagnostics)
|
17:30
|
Closing remarks from Chairman
|
发表于 2019-6-3 22:23